Maximilian Stahl, MD

Maximilian Stahl, MD, is the Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, Chief of the Duffy Hematology Firm at Yale-New Haven Hospital and an Assistant Professor of Medicine (Medical Oncology and Hematology) at Yale University School Of Medicine.

He cares for patients with hematologic malignancies at Smilow Cancer Hospital in New Haven with a particular focus on acute and chronic leukemias and myelodysplastic syndromes. Dr. Stahl joined Yale from Dana-Farber Cancer Institute and Harvard Medical School where he was an Assistant Professor of Medicine within the Adult Leukemia Program.

Dr. Stahl received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where he also served as chief medical resident. He then completed a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, where he also served as chief fellow, and a postdoctoral research fellowship at Rockefeller University.

His clinical research evaluates outcomes achieved with novel therapeutic approaches for AML, MDS, and MPNs, with a focus on identifying molecular predictors of these outcomes. Dr. Stahl actively leads clinical and translational research with the goal of bringing basic scientific discoveries from the lab to the clinic to benefit patients with leukemia. Towards this goal, he conducts early phase clinical trials testing novel treatment approaches. Dr. Stahl is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for MDS and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) focusing on early phase clinical trials of novel therapies for myeloid malignancies.

Dr. Stahl authored and co-authored more than 130 peer reviewed publications and has presented his research in multiple national and international meetings. He has received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award, the Leukemia & Lymphoma Society Translational Research Program Award and several ASH Abstract Achievement Awards. He is a member of the Editorial Board of Leukemia & Lymphoma and serves as an ad hoc reviewer for several journals including Blood, Blood Advances, Leukemia, Clinical Cancer Research, the British Journal of Haematology and Haematologica. He is also also a member of the National Comprehensive Cancer Network Clinical Practice Panel for AML and MDS.